Skip to Content
Morningstar

Compass Therapeutics Inc Ordinary Shares CMPX

Morningstar Rating
Unlock
Stock XNAS Rating as of
$1.56 −0.04 (2.50%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
CMPX is trading within a range we consider fairly valued.
Price
$1.55
Fair Value
$6.50
Uncertainty
Extreme
1-Star Price
$31.89
5-Star Price
$3.65
Economic Moat
Clp
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CMPX is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$1.60
Day Range
$1.41–1.71
52-Week Range
$1.15–3.62
Bid/Ask
$1.39 / $2.49
Market Cap
$214.64 Mil
Volume/Avg
258,143 / 349,137

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
32
Website
https://www.compasstherapeutics.com

Comparables

Valuation

View More
Metric
CMPX
IGMS
MRSN
Price/Earnings (Normalized)
 ———
Price/Book Value
 1.343.3811.46
Price/Sales
 —246.798.18
Price/Cash Flow
 ———
Price/Earnings
CMPX
IGMS
MRSN

Financial Strength

Metric
CMPX
IGMS
MRSN
Quick Ratio
 19.547.953.43
Current Ratio
 19.738.183.51
Interest Coverage
 ——−34.91
Quick Ratio
CMPX
IGMS
MRSN

Profitability

Metric
CMPX
IGMS
MRSN
Return on Assets (Normalized)
 −20.35%−45.69%−41.22%
Return on Equity (Normalized)
 −21.81%−90.75%−196.75%
Return on Invested Capital (Normalized)
 −26.16%−81.91%−129.55%
Return on Assets
CMPX
IGMS
MRSN
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSlxhnqmzcThbqn$585.2 Bil
VRTX
Vertex Pharmaceuticals IncGtkqhkpyxSrfvwq$110.9 Bil
REGN
Regeneron Pharmaceuticals IncFcgrkthqjNrvqls$107.6 Bil
MRNA
Moderna IncZzcgcqsHjzx$48.2 Bil
BNTX
BioNTech SE ADRBymlrjgNdz$22.3 Bil
ARGX
argenx SE ADRPxxxythjlKjzhm$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncKpbdrlfmQjgzn$19.0 Bil
BMRN
Biomarin Pharmaceutical IncVgwdtjcxXwdbp$15.3 Bil
INCY
Incyte CorpSpgmrydfPldrvn$13.0 Bil
RPRX
Royalty Pharma PLC Class AMcrfnkgwfTbktx$12.8 Bil

Sponsor Center